OCUL Covered Call Strategy
OCUL (Ocular Therapeutix, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
OCUL (Ocular Therapeutix, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $2.02B, a beta of 0.93 versus the broader market, a 52-week range of 6.23-16.44, average daily share volume of 5.4M, a public-listing history dating back to 2014, approximately 274 full-time employees. These structural characteristics shape how OCUL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.93 places OCUL roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a covered call on OCUL?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
Current OCUL snapshot
As of May 15, 2026, spot at $9.16, ATM IV 88.13%, IV rank 14.71%, expected move 25.27%. The covered call on OCUL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this covered call structure on OCUL specifically: OCUL IV at 88.13% is on the cheap side of its 1-year range, which means a premium-selling OCUL covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 25.27% (roughly $2.31 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated OCUL expiries trade a higher absolute premium for lower per-day decay. Position sizing on OCUL should anchor to the underlying notional of $9.16 per share and to the trader's directional view on OCUL stock.
OCUL covered call setup
The OCUL covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With OCUL near $9.16, the first option leg uses a $9.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed OCUL chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 OCUL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $9.16 | long |
| Sell 1 | Call | $9.50 | $0.65 |
OCUL covered call risk and reward
- Net Premium / Debit
- -$851.00
- Max Profit (per contract)
- $99.00
- Max Loss (per contract)
- -$850.00
- Breakeven(s)
- $8.51
- Risk / Reward Ratio
- 0.116
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
OCUL covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on OCUL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -99.9% | -$850.00 |
| $2.03 | -77.8% | -$647.58 |
| $4.06 | -55.7% | -$445.16 |
| $6.08 | -33.6% | -$242.73 |
| $8.11 | -11.5% | -$40.31 |
| $10.13 | +10.6% | +$99.00 |
| $12.16 | +32.7% | +$99.00 |
| $14.18 | +54.8% | +$99.00 |
| $16.20 | +76.9% | +$99.00 |
| $18.23 | +99.0% | +$99.00 |
When traders use covered call on OCUL
Covered calls on OCUL are an income strategy run on existing OCUL stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
OCUL thesis for this covered call
The market-implied 1-standard-deviation range for OCUL extends from approximately $6.85 on the downside to $11.47 on the upside. A OCUL covered call collects premium on an existing long OCUL position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether OCUL will breach that level within the expiration window. Current OCUL IV rank near 14.71% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on OCUL at 88.13%. As a Healthcare name, OCUL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to OCUL-specific events.
OCUL covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. OCUL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move OCUL alongside the broader basket even when OCUL-specific fundamentals are unchanged. Short-premium structures like a covered call on OCUL carry tail risk when realized volatility exceeds the implied move; review historical OCUL earnings reactions and macro stress periods before sizing. Always rebuild the position from current OCUL chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on OCUL?
- A covered call on OCUL is the covered call strategy applied to OCUL (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With OCUL stock trading near $9.16, the strikes shown on this page are snapped to the nearest listed OCUL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are OCUL covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the OCUL covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 88.13%), the computed maximum profit is $99.00 per contract and the computed maximum loss is -$850.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a OCUL covered call?
- The breakeven for the OCUL covered call priced on this page is roughly $8.51 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current OCUL market-implied 1-standard-deviation expected move is approximately 25.27%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on OCUL?
- Covered calls on OCUL are an income strategy run on existing OCUL stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current OCUL implied volatility affect this covered call?
- OCUL ATM IV is at 88.13% with IV rank near 14.71%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.